Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
Sarah J. Morgan, Ellis Coulter, Hannah L. Betts, George M. Solomon, John P. Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh, the PROMISE-Micro Study Group
Sarah J. Morgan, Ellis Coulter, Hannah L. Betts, George M. Solomon, John P. Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh, the PROMISE-Micro Study Group
View: Text | PDF
Research Letter Microbiology

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

  • Text
  • PDF
Abstract

Authors

Sarah J. Morgan, Ellis Coulter, Hannah L. Betts, George M. Solomon, John P. Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh, the PROMISE-Micro Study Group

×

Figure 1

Sputum microbiology after ETI.

Options: View larger image (or click on image) Download as PowerPoint
Sputum microbiology after ETI.
(A) Proportion of participants culture po...
(A) Proportion of participants culture positive for indicated pathogens (includes participants missing data at visit). *P < 0.05 by McNemar’s exact test. (B) Proportion of baseline-positive participants becoming repeatedly negative for indicated pathogen by culture (C) or culture and ddPCR (C&dd); n = number of participants analyzed. (C–H) Culture density in participants who were baseline culture positive for indicated pathogens including (C, E, and G) and not including (D, F, and H) culture-negative samples. Similar differences were apparent between all-data vs. data with culture-negative samples eliminated in by-participant averages (Supplemental Figure 1, C–H). Individual participants are indicated in black, averages in red. The limit of detection = 20 CFU/g. *P < 0.05 vs. baseline; #P < 0.05 vs. 1 month by mixed-effects analysis (C–H).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts